New drug combo aims to stop liver cancer recurrence after surgery
NCT ID NCT07324824
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether giving two drugs—sintilimab (an immunotherapy) and bevacizumab (a targeted therapy)—before surgery can help prevent liver cancer from coming back. The study includes 37 adults with resectable liver cancer that is beyond the Milan criteria, meaning it is more advanced than usual surgical limits. Participants will receive the drugs for a few cycles before surgery, and researchers will track how many remain cancer-free one year later.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sintilimab and bevacizumab biosimilar (immunotherapy and targeted therapy drugs)
What this could lead to
If successful, this combination could become a standard pre-surgery treatment to lower the chance of liver cancer returning after surgery.
What could go wrong
This is a small, early-phase study with only 37 participants and no comparison group. The treatment may cause side effects, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••